Immunotherapy Today

Immunotherapy News From Around The World

< Immunotherapy Today home

Author: btwatson

  • Harnessing T-cell 'stemness' could enhance cancer immunotherapy – Medical Xpress
    Harnessing T-cell 'stemness' could enhance cancer immunotherapy – Medical Xpress
  • Enfortumab Vedotin Effective in Urothelial Carcinoma After Chemo and Immunotherapy – Targeted Oncology
    Enfortumab Vedotin Effective in Urothelial Carcinoma After Chemo and Immunotherapy – Targeted Oncology
  • Editorial Article: Next-Generation Immunotherapy: Combining Virus-Specific T Cells with Other Immuno-Oncology Technologies to Treat Solid Tumors – SelectScience
    Editorial Article: Next-Generation Immunotherapy: Combining Virus-Specific T Cells with Other Immuno-Oncology Technologies to Treat Solid Tumors – SelectScience
  • The Promise and Limits of Cancer Immunotherapy Video – Technology Networks
    The Promise and Limits of Cancer Immunotherapy Video – Technology Networks
  • Cancer immunotherapy may have a dark side – Science Magazine
  • Enfortumab Vedotin Active After Chemo and Immunotherapy in Urothelial Carcinoma – OncLive
    Enfortumab Vedotin Active After Chemo and Immunotherapy in Urothelial Carcinoma – OncLive
  • Immuno-Oncology Company Elicio Therapeutics Launches with Novel Vaccine & Immunotherapy Platform to Treat an Array of Cancers – Business Wire
    Immuno-Oncology Company Elicio Therapeutics Launches with Novel Vaccine & Immunotherapy Platform to Treat an Array of Cancers – Business Wire
  • New study confirms EpCAM as promising target for cancer immunotherapy – EurekAlert
    New study confirms EpCAM as promising target for cancer immunotherapy – EurekAlert
  • Next-Generation Immunotherapy: Combining Virus-Specific T Cells with Other Immuno-Oncology Technologies to Treat Solid Tumors – SelectScience
    Next-Generation Immunotherapy: Combining Virus-Specific T Cells with Other Immuno-Oncology Technologies to Treat Solid Tumors – SelectScience
  • Benefitting From Immunotherapy in CRC – Targeted Oncology
    Benefitting From Immunotherapy in CRC – Targeted Oncology
< Newer Entries   |   Older Entries >
Copyright 2018 ImmunoTherapyToday.com